RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 144 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.45 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $237,678 | +7.1% | 31,069 | +4.6% | 0.00% | 0.0% |
| Q2 2023 | $221,836 | +15.5% | 29,697 | +3.1% | 0.00% | 0.0% |
| Q1 2023 | $192,109 | -23.6% | 28,802 | -11.7% | 0.00% | 0.0% |
| Q4 2022 | $251,431 | -18.4% | 32,611 | +12.8% | 0.00% | 0.0% |
| Q3 2022 | $308,000 | +35.7% | 28,904 | +3.4% | 0.00% | 0.0% |
| Q2 2022 | $227,000 | -16.5% | 27,950 | -26.7% | 0.00% | 0.0% |
| Q1 2022 | $272,000 | -66.7% | 38,107 | -20.0% | 0.00% | -50.0% |
| Q4 2021 | $816,000 | +308.0% | 47,649 | +769.2% | 0.00% | +100.0% |
| Q2 2021 | $200,000 | – | 5,482 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Obvious Management Services, L.L.C. | 5,977,631 | $42,800,000 | 100.00% |
| Two Sigma Ventures, LP | 1,806,800 | $12,937,000 | 74.73% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $28,290,000 | 31.54% |
| MV Management XI, L.L.C. | 1,971,908 | $14,119,000 | 9.80% |
| Data Collective IV GP, LLC | 5,941,120 | $42,538,000 | 9.03% |
| ArchPoint Investors | 1,267,430 | $9,075,000 | 3.13% |
| MIC Capital Management UK LLP | 1,388,889 | $9,944,000 | 1.94% |
| HARVARD MANAGEMENT CO INC | 1,509,254 | $10,806,000 | 1.09% |
| Samsara BioCapital, LLC | 539,236 | $3,861,000 | 0.97% |
| Pinz Capital Management, LP | 142,168 | $1,018,000 | 0.64% |